ESR1 and breast carcinoma: For these reasons, determination of estrogen receptor (ER) and progesterone receptor (PgR) status has become an essential part of the clinical evaluation of all breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from hormone therapy.2–8 Immunohistochemistry (IHC) is currently the most common method used for determining ER and PgR status.